HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 12-11-2019, 03:22 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Thumbs up remarkable new drug for her2+mbc effective after many previous lines of treatment

HEALTH NEWSDECEMBER 11, 2019 / 2:12 PM / UPDATED 9 HOURS AGO
AstraZeneca-Daiichi drug halts cancer for months in first readout

(Reuters) - An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
Patients on trastuzumab deruxtecan, also known as DS-8201, who had already undergone roughly six prior treatment courses, were saw no further progression for a median of 16.4 months.

Jose Baselga, AstraZeneca’s head of oncology research and development, said this patient group would normally encounter further cancer deterioration after about six months.

“This is a totally unprecedented clinical benefit,” he said of the so-called antibody-drug conjugate, which links powerful cell toxins to antibodies that cling to cancer cells, sparing the healthy ones that would be damaged in normal chemotherapy.

AstraZeneca signed a licensing and collaboration deal in March which committed the British drugmaker to paying up to $6.9 billion to its Japanese partner Daiichi.

ADVERTISEMENT


Analysts have said the deal, and a $3.5 billion share issue to fund it, will require AstraZeneca to focus on cash flow.

Baselga added that as patients exhaust treatment options each new approach - or line of treatment - that is tried normally brings a lower clinical benefit than the one before.

The study dubbed DESTINY-Breast01 is the first of an envisaged 28 trials with trastuzumab deruxtecan.

Later trials will tackle breast cancer in earlier lines of treatment and also lung and gastric cancer.

“If this benefit is observed in this line of therapy I think that this drug can be incredibly beneficial in patients with earlier disease,” said Baselga.

Daiichi and AstraZeneca, which said in May that the main goal of the trial had been met, have already put in a request for approval with the U.S. Food and Drug Administration.

The full results are due to be presented at the San Antonio Breast Cancer Symposium this week.

Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Gopakumar Warrier/Keith Weir/Alexander Smith
Our Standards:The Thomson Reuters Trust Principles.
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 08:16 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter